Quick Answer Enact Holdings, Inc. reported Cash and Equivalents of $582.49 million for fiscal year 2025. Enact Holdings, Inc. Cash and Equivalents — Annual History Fiscal Year Cash and Equivalents YoY Change 2025 $582.49M -2.8% 2024 $599.43M -2.6% 2023 $615.68M +19.8% 2022 $513.77M +20.7% 2021 $425.83M -6.0% 2020 $452.79M — Quarterly Cash and Equivalents Quarter … Read more
Quick Answer Enact Holdings, Inc. reported Total Assets of $6.89 billion for fiscal year 2025. Enact Holdings, Inc. Total Assets — Annual History Fiscal Year Total Assets YoY Change 2025 $6.89B +5.7% 2024 $6.52B +5.3% 2023 $6.19B +8.4% 2022 $5.71B -2.7% 2021 $5.87B +3.8% 2020 $5.65B — Quarterly Total Assets Quarter Ending Total Assets YoY … Read more
Quick Answer Enact Holdings, Inc. reported Net Income of $674.24 million for fiscal year 2025. Enact Holdings, Inc. Net Income — Annual History Fiscal Year Net Income YoY Change 2025 $674.24M -2.0% 2024 $688.07M +3.4% 2023 $665.51M +21.7% 2021 $546.68M +47.6% 2020 $370.42M -45.3% 2019 $677.63M — Quarterly Net Income Quarter Ending Net Income YoY … Read more
Quick Answer Enact Holdings, Inc. reported Diluted EPS of $4.52 per share for fiscal year 2025. Enact Holdings, Inc. Diluted EPS — Annual History Fiscal Year Diluted EPS YoY Change 2025 $4.52 +3.4% 2024 $4.37 +6.3% 2023 $4.11 -4.6% 2022 $4.31 +28.3% 2021 $3.36 +48.0% 2020 $2.27 -45.4% 2019 $4.16 — Quarterly Diluted EPS Quarter … Read more
Quick Answer Enact Holdings, Inc. reported Total Revenue of $1.24 billion for fiscal year 2025. Enact Holdings, Inc. — Key Financials by Year Metric 2025 2024 2023 2022 2021 2020 Total Revenue $1.24B+2.8% $1.20B+4.2% $1.15B+5.4% $1.10B-2.0% $1.12B+1.0% $1.11B+13.0% Net Income $674.24M-2.0% $688.07M+3.4% $665.51M — $546.68M+47.6% $370.42M-45.3% Diluted EPS $4.52+3.4% $4.37+6.3% $4.11-4.6% $4.31+28.3% $3.36+48.0% $2.27-45.4% Total … Read more
Quick Answer Enact Holdings, Inc. reported Total Revenue of $1.24 billion for fiscal year 2025. Enact Holdings, Inc. Total Revenue — Annual History Fiscal Year Total Revenue YoY Change 2025 $1.24B +2.8% 2024 $1.20B +4.2% 2023 $1.15B +5.4% 2022 $1.10B -2.0% 2021 $1.12B +1.0% 2020 $1.11B +13.0% 2019 $978.85M — Quarterly Total Revenue Quarter Ending … Read more
Quick Answer Acrivon Therapeutics, Inc. reported Shares Outstanding of 31.65 million shares for fiscal year 2025. Acrivon Therapeutics, Inc. Shares Outstanding — Annual History Fiscal Year Shares Outstanding YoY Change 2025 31.65M +1.3% 2024 31.23M +38.7% 2023 22.52M +2.7% 2022 21.92M +1138.7% 2021 1.77M — Quarterly Shares Outstanding Quarter Ending Shares Outstanding YoY QoQ September … Read more
Quick Answer Acrivon Therapeutics, Inc. reported Operating Income of -$84.11 million for fiscal year 2025. Acrivon Therapeutics, Inc. Operating Income — Annual History Fiscal Year Operating Income YoY Change 2025 -$84.11M +5.7% 2024 -$89.20M -32.9% 2023 -$67.10M -105.5% 2022 -$32.66M -101.8% 2021 -$16.18M — Quarterly Operating Income Quarter Ending Operating Income YoY QoQ September 30, … Read more
Quick Answer Acrivon Therapeutics, Inc. reported R&D Expense of $59.99 million for fiscal year 2025. Acrivon Therapeutics, Inc. R&D Expense — Annual History Fiscal Year R&D Expense YoY Change 2025 $59.99M -6.3% 2024 $63.99M +39.0% 2023 $46.02M +92.2% 2022 $23.95M — Quarterly R&D Expense Quarter Ending R&D Expense YoY QoQ September 30, 2025 $13.65M -27.7% … Read more
Quick Answer Acrivon Therapeutics, Inc. reported Stockholders Equity of $112.52 million for fiscal year 2025. Acrivon Therapeutics, Inc. Stockholders Equity — Annual History Fiscal Year Stockholders Equity YoY Change 2025 $112.52M -36.4% 2024 $176.79M +45.9% 2023 $121.19M -28.9% 2022 $170.47M +816.0% 2021 -$23.81M -183.0% 2020 -$8.41M — Quarterly Stockholders Equity Quarter Ending Stockholders Equity YoY … Read more